

**Faramarz Ismail-Beigi, M.D., Ph.D.**

**Professor of Medicine, Case**

**Division of Clinical and Molecular Endocrinology, UHC**

**Education:**

Ph.D. - 1972 - University of California, Berkeley and San Francisco, CA; Biophysics

M.D. - 1966 - The Johns Hopkins School of Medicine, Baltimore, MD; Medicine

B.A. - 1962 - Berea College, Berea, Kentucky

**Postgraduate Training:**

1966-67 - Intern in Medicine, Osler Medical Service, The Johns Hopkins Hospital, Baltimore, MD

1967-68 - Assistant Resident in Medicine, Osler Medical Service, The Johns Hopkins Hospital, Baltimore, Maryland

1968-71 - Research Fellow and Ph.D. Candidate, Cardiovascular Research Institute, University of California School of Medicine, San Francisco, and Department of Biophysics, University of California, Berkeley, California

1971-72 - Senior Assistant Resident in Medicine and Hematology, The Johns Hopkins Hospital, Baltimore, Maryland

**Certification:**

1972 - American Board of Internal Medicine

**Current Grant Support:**

NIH-NHLBI-HC-99-16; Action to Control Cardiovascular Risk in Diabetes (ACCORD); Saul Genuth, PI of the Ohio/Michigan Network Center; F. Ismail-Beigi, co-PI; 9/30/99 - 9/30/09, \$3,581,514 for the current year.

NIH-NHLBI-HC-99-16; Action to Control Cardiovascular Risk in Diabetes (ACCORD); F. Ismail-Beigi, PI of the University Hospitals of Cleveland site; 9/30/99 - 9/30/09, \$250,000 direct cost for the current year.

NIH-NHLBI-HC-99-16; Action to Control Cardiovascular Risk in Diabetes (ACCORD); F. Ismail-Beigi, PI of the Cleveland VA site; 9/30/99 - 9/30/09, \$350,000 direct cost for the current year.

**Publications:**

1. Ismail-Beigi, F., Catalano, P. M., and Hanson, R W. Metabolic programming: Fetal origins of obesity and metabolic syndrome in the adult. *Am. J. Physiol.* 291: E439-E440 (2006).
2. Kasturi, S., Bederman, I. R., Christopher, B., Previs, S. F., and Ismail-Beigi, F. Exposure to azide markedly decreases mRNAs encoding cholesterol synthetic enzymes through an AMPK-independent pathway. *J. Cell. Biochem.* 100: 1034-1044 (2007).
3. Jing, M, and Ismail-Beigi, F. Critical role of 5'-AMP protein kinase in the stimulation of glucose transport in response to inhibition of oxidative phosphorylation. *Am. J. Physiol.* 292: C477-C487 (2007).
4. Landau, B. L., Spring-Robinson, C. L., Muzic Jr., R. F., Rachdaoui, N., Rubin, D., Marc S. Berridge, M.S., Schumann, W.C., Chandramouli, V., Kern, T. S., and Ismail-Beigi, F. 6-Fluoro-6-deoxy-D-glucose as a Tracer of Glucose Transport. *Am. J. Physiol.* 293: E237-E245 (2007).
5. Kasturi, S, and Ismail-Beigi, F. Effect of thyroid hormone on the distribution of Na, K-ATPase in ventricular myocardium. *Arch. Biochem. Biophys.* 475: 121-127 (2008).
6. Ismail-Beigi, F. (Study Investigator). Riddle, M., Rosenstock, J., and Gerich, J. The treat-to-target trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. *Diabetes Care* 26: 3080-3086 (2003).
7. The ACCORD STUDY GROUP. The Action to Control Cardiovascular Risk in Diabetes Trial: A multidisciplinary approach to control of cardiovascular risk in type 2 diabetes mellitus. *Practical Diabetology* 23: 2-7 (2004).

8. Al-Arouj, M., Bouguerra, R., Buse, J., Hafez, S., Hassanein, M., Ibrahim-Asharaf, M., Ismail-Beigi, F., El-Kebbi, I., Al-Khatib, U., Kishawi, S., Al-Madani, A., Mishal, A. A., Al-Maskari, M., Ben-Nakhi, A., and Al-Rubean, K. Recommendations for management of diabetes during Ramadan. Diabetes Care 28: 2305-2311 (2005).
9. The BARI 2D STUDY GROUP. Treatment of Coronary Artery Disease and Type 2 Diabetes Mellitus: The Rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. *Am. J. Cardiol.* 97 (Suppl. 12A): 1G-66G (2006).
10. The ACCORD STUDY GROUP. Rationale, Design, and Methods of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. *Am. J. Cardiol.* 99 (Supplement 12A): 1i-122i (2007).
11. Gerstein, H. C., Riddle, M., Kendall, D. M., Cohen, R. M., Golland, R., Feinglos, M. N., Kirk, J. K., Hamilton, B. P., Ismail-Beigi, F., and Feeney, P. Glycemic Treatment Strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. *Am. J. Cardiol.* 99 (Supplement 12A): 34i-43i (2007).
12. The ACCORD STUDY GROUP (member of the writing team). Effects of Intensive Glucose Lowering in Type 2 Diabetes. *New Engl. J. Med.* 358: 2545-2559 (2008).